Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS
Question
Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS
Direct answer
A 45.9% ORR in platinum-resistant ovarian cancer de-risks Phase 3 clinical development and potential commercial peak sales value for GMAB's ADC pipeline. — bullish pressure on GMAB via clinical pipeline de-risking boosting ADC portfolio NPV.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-04
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS”, revision 1, evidence through 2026-10-04. https://marketontology.com/catalysts/2026-10-04/genmab-phase-2-ovarian-cancer-trial-demonstrates-45-9-orr-and-9-5m-median-pfs-b00ad3
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| GMAB | ▲Bull | 1–4 weeks | clinical pipeline de-risking boosting ADC portfolio NPV | 70 |
Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS
A 45.9% ORR in platinum-resistant ovarian cancer de-risks Phase 3 clinical development and potential commercial peak sales value for GMAB's ADC pipeline. — bullish pressure on GMAB via clinical pipeline de-risking boosting ADC portfolio NPV.
Phase 2 trial shows 45.9% ORR and 9.5-month PFS in platinum-resistant ovarian cancer.
- SourcePhase 2 trial shows 45.9% ORR and 9.5-month PFS in platinum-resistant ovarian cancer.
- TransmissionA 45.9% ORR in platinum-resistant ovarian cancer de-risks Phase 3 clinical development and potential commercial peak sales value for GMAB's ADC pipeline.
- SummaryGenmab released positive Phase 2 RAINFOL-01 clinical trial data for Rina-S in ovarian cancer. Results showed a 45.9% objective response rate with 9.5 months median progression-free survival. The data supports advancement toward registrational oncology studies for antibody-drug conjugates.
- GMABDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- GMAB closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- GMAB price vs. pre-event level
- GMAB volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results · press_release · 2026-10-03
Related catalysts
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian CancerGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian CancerGMAB
- 2026-10-04Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trialGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer TrialGMAB
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.